Copyright ©The Author(s) 2023.
World J Gastrointest Oncol. Oct 15, 2023; 15(10): 1691-1705
Published online Oct 15, 2023. doi: 10.4251/wjgo.v15.i10.1691
Table 1 Summary of completed clinical trials investigating immunotherapy in advanced pancreatic cancer patients
No. of patients
ORR (%)
Mean OS (mo)
Mean PFS (mo)
Le et al[50], 2013Ipilimumab vs ipilimumab plus GVAX15/15-3.6/5.7 1-yr OS (%) 7/27-Ipilimumab combined with GVAX was efficacious in advanced pancreatic cancer treatment
Kamath et al[52], 2020Ipilimumab plus gemcitabine21146.92.78Gemcitabine plus Ipilimumab is a safe and tolerable regimen for advanced pancreatic cancer with a similar response rate to gemcitabine alone
Aglietta et al[53], 2014Tremelimumab plus gemcitabine34-7.4-Tremelimumab with gemcitabine had a favorable safety and tolerability profile, indicating that it should be studied further in patients with advanced pancreatic cancer
Renouf et al[54], 2022Gemcitabine, nab-paclitaxel, durvalumab, and tremelimumab vs gemcitabine and nab-paclitaxel119/6130.3/23.39.8/8.85.5/5.4The results did not demonstrate a benefit from adding durvalumab and tremelimumab to gemcitabine and nab-paclitaxel as a first line therapy in advanced pancreatic cancer patients
Reiss et al[57], 2022Niraparib and nivolumab vs niraparib and ipilimumab91 (46/45)7.1/15.413.2/17.31.9/8.1The advantage of niraparib with ipilimumab maintenance treatment extended to patients who did not have known DDR mutations, indicating that the impact is not dependent on DDR deficit
Bockorny et al[67], 2021Motixafortide, pembrolizumab and FOLFIRINOX4313.26.63.8In a group with poor prognoses and aggressive diseases, motixafortide and pembrolizumab in conjunction with FOLFIRINOX demonstrated effectiveness. The therapy was well tolerated
O’Reilly et al[69], 2019Durvalumab vs durvalumab and tremelimumab64 (32/32)0/3.13.6/3.11.5/1.5The medication was well tolerated, and both durvalumab monotherapy and durvalumab combined with tremelimumab were effective in treating advanced pancreatic cancer patients with a poor prognosis